OncoMatch/Clinical Trials/NCT07174583
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Is NCT07174583 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including IDE849 and durvalumab for small-cell lung cancer.
Treatment: IDE849 · durvalumab · IDE161 · Carboplatin — This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Small Cell Lung Cancer
Neuroendocrine Tumor
Tumor Agnostic
Biomarker criteria
Required: DLL3 moderate/high expression (moderate/high)
DLL3+ solid tumors; Subjects with other solid tumors demonstrated to express moderate/high expression of DLL3
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — Small Cell Lung Cancer
For SCLC, this includes platinum-based therapy ... must have radiologically progressed or recurred after previous standard treatment.
Must have received: anti-PD-1 therapy — Small Cell Lung Cancer
For SCLC, this includes ... programmed death-1/programmed death-ligand 1 inhibitors ... must have radiologically progressed or recurred after previous standard treatment.
Cannot have received: DLL3 antibody-drug conjugate with Topo1 inhibitor payload
Exception: except for participants enrolling to receive the IDE161 combination
Have prior treatment with DLL3 ADC with a Topo1 inhibitor payload (except for participants enrolling to receive the IDE161 combination).
Lab requirements
Blood counts
adequate bone marrow and organ function within 7 days of the first dose (no use of any blood components and/or cell growth factors within 14 days prior to the start of the study treatment)
Have adequate bone marrow and organ function within 7 days of the first dose (no use of any blood components and/or cell growth factors within 14 days prior to the start of the study treatment).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- Sarah Cannon Research Institute at Florida Cancer Specialists · Orlando, Florida
- Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne North Office · Fort Wayne, Indiana
- START Midwest · Grand Rapids, Michigan
- The Cancer and Hematology Centers · Grand Rapids, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07174583 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior DLL3 antibody-drug conjugate with Topo1 inhibitor payload disqualifies patients from enrollment.
Does this trial require DLL3?
Yes, DLL3 moderate/high expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify